$SRTS
Sensus Healthcare, Inc. Stock $srts

$srts Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024023093 Filed on March 15, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$10.66M	$12.57M	$24.41M
YoY Change	212.33%	-4.11%	-45.2%
Cost Of Revenue	$4.001M	$4.737M	$10.35M
YoY Change	123.27%	-0.36%	-30.59%
Gross Profit	$6.662M	$7.829M	$14.06M
YoY Change	310.73%	-6.25%	-52.54%
Gross Profit Margin	62.48%	62.3%	57.61%
Selling, General & Admin	$2.849M	$1.574M	$10.76M
YoY Change	-17.73%	-47.88%	-5.05%
% of Gross Profit	42.76%	20.1%	76.56%
Research & Development	$926.0K	$678.0K	$3.678M
YoY Change	-15.66%	-41.45%	6.3%
% of Gross Profit	13.9%	8.66%	26.16%
Depreciation & Amortization	$70.00K	$55.00K	$226.0K
YoY Change	-4.11%	-25.68%	-28.25%
% of Gross Profit	1.05%	0.7%	1.61%
Operating Expenses	$3.775M	$2.252M	$14.44M
YoY Change	-17.23%	-46.1%	-2.4%
Operating Profit	$2.887M	$5.577M	-$382.0K
YoY Change	-198.23%	33.64%	-102.58%
Interest Expense	$214.0K	$228.0K	$992.0K
YoY Change	-188.07%	-2.98%	161.05%
% of Operating Profit	7.41%	4.09%
Other Income/Expense, Net	$214.0K		$1.034M
YoY Change	-11.93%		-92.14%
Pretax Income	$3.101M	$5.805M	$652.0K
YoY Change	-215.02%	31.69%	-97.67%
Income Tax	$827.0K	$1.595M	$167.0K
% Of Pretax Income	26.67%	27.48%	25.61%
Net Earnings	$2.274M	$4.210M	$485.0K
YoY Change	-220.06%	48.71%	-98.0%
Net Earnings / Revenue	21.33%	33.5%	1.99%
Basic Earnings Per Share	$0.14		$0.03
Diluted Earnings Per Share	$0.14	$0.26	$0.03
COMMON SHARES
Basic Shares Outstanding	16.39M shares	16.38M shares	16.26M shares
Diluted Shares Outstanding	16.32M shares		16.27M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.73M	$23.15M	$23.15M
YoY Change	-23.85%	-9.29%	-9.29%
Cash & Equivalents	$14.73M	$23.15M	$23.15M
Short-Term Investments
Other Short-Term Assets	$1.169M	$888.0K	$888.0K
YoY Change	-89.03%	-87.98%	-87.98%
Inventory	$14.72M	$14.85M	$14.85M
Prepaid Expenses	$3.671M	$2.986M
Receivables	$19.63M	$10.65M	$10.65M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$53.91M	$49.53M	$49.53M
YoY Change	9.87%	-7.78%	-7.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$633.0K	$1.238M	$1.238M
YoY Change	59.45%	-0.08%	-0.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$688.0K	$2.944M	$2.944M
YoY Change	64.2%	69.49%	69.49%
Total Long-Term Assets	$3.360M	$4.182M	$4.182M
YoY Change	-22.38%	38.2%	38.2%
TOTAL ASSETS
Total Short-Term Assets	$53.91M	$49.53M	$49.53M
Total Long-Term Assets	$3.360M	$4.182M	$4.182M
Total Assets	$57.27M	$53.71M	$53.71M
YoY Change	7.26%	-5.33%	-5.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.703M	$2.793M	$2.793M
YoY Change	-24.86%	-49.41%	-49.41%
Accrued Expenses	$191.0K	$187.0K	$187.0K
YoY Change	-0.52%	-1.58%	-1.58%
Deferred Revenue		$657.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.473M	$4.212M	$4.212M
YoY Change	-11.24%	-45.28%	-45.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$593.0K	$656.0K	$656.0K
YoY Change	-34.69%	-32.3%	-32.3%
Total Long-Term Liabilities	$593.0K	$656.0K	$656.0K
YoY Change	-34.69%	-32.3%	-32.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.473M	$4.212M	$4.212M
Total Long-Term Liabilities	$593.0K	$656.0K	$656.0K
Total Liabilities	$6.066M	$4.868M	$4.868M
YoY Change	-14.25%	-43.83%	-43.83%
SHAREHOLDERS EQUITY
Retained Earnings	$9.061M	$6.787M
YoY Change	105.56%	7.7%
Common Stock	$169.0K	$169.0K
YoY Change	-99.63%	-99.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.519M	$3.519M
YoY Change	1.32%	2.51%
Treasury Stock Shares
Shareholders Equity	$51.21M	$48.84M	$48.84M
YoY Change
Total Liabilities & Shareholders Equity	$57.27M	$53.71M	$53.71M
YoY Change	7.26%	-5.33%	-5.33%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$2.274M	$4.210M	$485.0K
YoY Change	-220.06%	48.71%	-98.0%
Depreciation, Depletion And Amortization	$70.00K	$55.00K	$226.0K
YoY Change	-4.11%	-25.68%	-28.25%
Cash From Operating Activities	-$8.187M	$2.665M	-$2.145M
YoY Change	36.52%	-126.35%	51.91%
INVESTING ACTIVITIES
Capital Expenditures	$233.0K	-$1.000K	$229.0K
YoY Change	23.28%	-110.0%	44.03%
Acquisitions
YoY Change
Other Investing Activities		$2.000K	$42.00K
YoY Change			-99.72%
Cash From Investing Activities	-$233.0K	$3.000K	-$187.0K
YoY Change	23.28%	-130.0%	-101.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-10.00K	-$40.00K
YoY Change		-99.48%	-98.35%
NET CHANGE
Cash From Operating Activities	-$8.187M	2.665M	-$2.145M
Cash From Investing Activities	-$233.0K	3.000K	-$187.0K
Cash From Financing Activities		-10.00K	-$40.00K
Net Change In Cash	-$8.420M	2.658M	-$2.372M
YoY Change	36.25%	-122.05%	-121.56%
FREE CASH FLOW
Cash From Operating Activities	-$8.187M	$2.665M	-$2.145M
Capital Expenditures	$233.0K	-$1.000K	$229.0K
Free Cash Flow	-$8.420M	$2.666M	-$2.374M
YoY Change	36.11%	-126.34%	51.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	srts	Decrease In Operating Lease Rightofuse Asset And Operating Lease Liabilities DecreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilities		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37714
CY2023	dei	Entity Registrant Name EntityRegistrantName	Sensus Healthcare, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-1647271
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	851 Broken Sound Pkwy
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	NW #215
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33487
CY2023	dei	City Area Code CityAreaCode	(561)
CY2023	dei	Local Phone Number LocalPhoneNumber	922-5808
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	SRTS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	45722493	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16394171	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23148000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25520000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10645000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17299000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11861000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	3501000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2986000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6261000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	888000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	660000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	49528000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	53241000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	464000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	243000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2140000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1713000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	774000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	996000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	804000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	542000	usd
CY2023Q4	us-gaap	Assets Assets	53710000	usd
CY2022Q4	us-gaap	Assets Assets	56735000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2793000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5521000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	538000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	403000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	187000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	190000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	37000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	890000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	657000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	693000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4212000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7697000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	596000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	830000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	60000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	139000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4868000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8666000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16907095	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16374171	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16902761	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16390419	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	169000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	169000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45405000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	45031000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	532924	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	512342	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3519000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3433000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	6787000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	6302000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	48842000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48069000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53710000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56735000	usd
CY2023	us-gaap	Revenues Revenues	24405000	usd
CY2022	us-gaap	Revenues Revenues	44532000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10345000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14904000	usd
CY2023	us-gaap	Gross Profit GrossProfit	14060000	usd
CY2022	us-gaap	Gross Profit GrossProfit	29628000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5608000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6329000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5156000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5008000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3678000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3460000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	14442000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	14797000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-382000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	14831000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	42000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	12779000	usd
CY2023	us-gaap	Interest Expense InterestExpense	-992000	usd
CY2022	us-gaap	Interest Expense InterestExpense	-380000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1034000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13159000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	652000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	27990000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3746000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	485000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	24244000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.47
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.46
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16259254	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16480991	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16266139	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16618214	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26015000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	187000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	731000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	2999000	usd
CY2022	srts	Surrender Of Shares For Tax Withholding On Stock Compensation SurrenderOfSharesForTaxWithholdingOnStockCompensation	-109000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	24244000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48069000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	359000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	46000	usd
CY2023	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	27000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	31000	usd
CY2023	srts	Surrender Of Shares For Tax Withholding On Stock Compensation SurrenderOfSharesForTaxWithholdingOnStockCompensation	-59000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	485000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	48842000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	485000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	24244000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	7000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	145000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	275000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	315000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	42000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	12779000	usd
CY2022	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	197000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	186000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	194000	usd
CY2023	srts	Provision For Product Warranties ProvisionForProductWarranties	-603000	usd
CY2022	srts	Provision For Product Warranties ProvisionForProductWarranties	-722000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	328000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	187000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-427000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1713000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6647000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5314000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8577000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3191000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3275000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4774000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	228000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-711000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	312000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	417000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2728000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	799000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-201000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-199000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-853000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	890000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-115000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-602000	usd
CY2023	srts	Increase Decrease Product Warranties IncreaseDecreaseProductWarranties	468000	usd
CY2022	srts	Increase Decrease Product Warranties IncreaseDecreaseProductWarranties	827000	usd
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-2630000	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-25656000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2145000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1412000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	229000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	159000	usd
CY2023	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	42000	usd
CY2022	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	15000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-187000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	14841000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	27000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2999000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	59000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	109000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	51000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	46000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	731000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-40000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2428000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2372000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11001000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25520000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14519000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23148000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25520000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1440000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4570000	usd
CY2022	srts	Decrease In Operating Lease Rightofuse Asset And Operating Lease Liabilities DecreaseInOperatingLeaseRightofuseAssetAndOperatingLeaseLiabilities	1045000	usd
CY2023	srts	Ppp Loanforgiveness Portions PPPLoanforgivenessPortions	-217000	usd
CY2022	srts	Ppp Loanforgiveness Portions PPPLoanforgivenessPortions	-48000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.</p>
CY2023	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	853500	usd
CY2023	us-gaap	Change In Reporting Entity Earnings Per Share Basic ChangeInReportingEntityEarningsPerShareBasic	0.05
CY2023	us-gaap	Change In Reporting Entity Earnings Per Share Diluted ChangeInReportingEntityEarningsPerShareDiluted	0.05
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i>Reclassification of Prior Year Presentation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current year presentation. The reclassifications are limited to the consolidated balance sheets and statements of cash flow and have no impact on the reported results of operations.</p>
CY2023	us-gaap	Revenues Revenues	24405000	usd
CY2022	us-gaap	Revenues Revenues	44532000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	1434000	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	4189000	usd
CY2022	srts	Amounts Invoiced AmountsInvoiced	3587000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	832000	usd
CY2023	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	2842000	usd
CY2023	srts	Amounts Invoiced AmountsInvoiced	2727000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	717000	usd
CY2023Q4	srts	Revenue Remaining Performance Obligation Year One RevenueRemainingPerformanceObligationYearOne	621000	usd
CY2023Q4	srts	Revenue Remaining Performance Obligation Year Two RevenueRemainingPerformanceObligationYearTwo	40000	usd
CY2023Q4	srts	Revenue Remaining Performance Obligation Year Three RevenueRemainingPerformanceObligationYearThree	20000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	681000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-variant: small-caps"><b><i>Concentration</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One customer in the U.S. accounted for approximately 61% and 73% of revenue for the years ended December 31, 2023 and 2022, respectively, and 85% and 91% of the accounts receivable as of December 31, 2023 and 2022, respectively.</p>
CY2023	us-gaap	Revenues Revenues	24405000	usd
CY2023	srts	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2022	us-gaap	Revenues Revenues	44532000	usd
CY2022	srts	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	0	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	107000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	7000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	145000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	217000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	48000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	89750	shares
CY2023	us-gaap	Advertising Expense AdvertisingExpense	1200000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	900000	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	15000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2347000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2374000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1883000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2131000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	464000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	243000	usd
CY2023	us-gaap	Depreciation Depreciation	226000	usd
CY2022	us-gaap	Depreciation Depreciation	219000	usd
CY2022Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	7500000	usd
CY2023Q3	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	10000000	usd
CY2023Q4	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	10000000	usd
CY2023	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0788	pure
CY2023	us-gaap	Line Of Credit Facility Asset Restrictions LineOfCreditFacilityAssetRestrictions	$3,500,000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	508000	usd
CY2022	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	722000	usd
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	827000	usd
CY2022Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	403000	usd
CY2023	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	603000	usd
CY2023	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	468000	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	538000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	186000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	194000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	223000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	229000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	236000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	181000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	869000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	86000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	783000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.05	pure
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	201000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	199000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	228000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	255000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31000	usd
CY2023	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	10300000	usd
CY2022	us-gaap	Increase Decrease In Finished Goods And Work In Process Inventories IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories	13700000	usd
CY2023	srts	Finished Goods Received FinishedGoodsReceived	12700000	usd
CY2022	srts	Finished Goods Received FinishedGoodsReceived	11000000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3000000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6300000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	89000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	95000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	11155	shares
CY2022	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	10096	shares
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	9427	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	312973	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	58973	shares
CY2020Q1	srts	Restricted Vest Percentage RestrictedVestPercentage	0.25	pure
CY2021Q3	srts	Restricted Vest Percentage RestrictedVestPercentage	0.25	pure
CY2021Q3	srts	Restricted Grant Percentage RestrictedGrantPercentage	0.25	pure
CY2022Q4	srts	Restricted Vest Percentage RestrictedVestPercentage	0.25	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.96
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	405000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y6M
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	249000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2977000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	345000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2482000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-369000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	2218000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-58000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-369000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-55000	usd
CY2023	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	167000	usd
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	7253000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3507000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3746000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.097	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.073	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.063	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.004	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.09	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.011	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.019	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.009	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.223	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.125	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.256	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.134	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	814000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	849000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	103000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	117000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	762000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	209000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	257000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	404000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	37000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	35000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	367000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	290000	usd
CY2023Q4	srts	Deferred Tax Asset Lease Accounting Net DeferredTaxAssetLeaseAccountingNet	2000	usd
CY2022Q4	srts	Deferred Tax Asset Lease Accounting Net DeferredTaxAssetLeaseAccountingNet	6000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2342000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1910000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	185000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	185000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2157000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1725000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	17000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	12000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	17000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	12000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2140000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	1713000	usd
CY2023	us-gaap	Income Tax Holiday Aggregate Dollar Amount IncomeTaxHolidayAggregateDollarAmount	7600000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	367000	usd
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits		usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2022Q4	us-gaap	Other Borrowings OtherBorrowings		usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001494891

Files In Submission

Name	View Source	Status
0001213900-24-023093-index-headers.html	Edgar Link	pending
0001213900-24-023093-index.html	Edgar Link	pending
0001213900-24-023093.txt	Edgar Link	pending
0001213900-24-023093-xbrl.zip	Edgar Link	pending
ea0201582-10k_sensus.htm	Edgar Link	pending
ea020158201ex23-1_sensus.htm	Edgar Link	pending
ea020158201ex31-1_sensus.htm	Edgar Link	pending
ea020158201ex31-2_sensus.htm	Edgar Link	pending
ea020158201ex32-1_sensus.htm	Edgar Link	pending
ea020158201ex32-2_sensus.htm	Edgar Link	pending
ea020158201ex97-1_sensus.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex23-1_002.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0201582-10k_sensus_htm.xml	Edgar Link	completed
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
srts-20231231.xsd	Edgar Link	pending
srts-20231231_def.xml	Edgar Link	unprocessable
srts-20231231_lab.xml	Edgar Link	unprocessable
srts-20231231_pre.xml	Edgar Link	unprocessable
srts-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SRTS
Sensus Healthcare, Inc. Stock $srts

2024 Q1 Form 10-K Financial Statement

#000121390024023093 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRTS Sensus Healthcare, Inc. Stock $srts

2024 Q1 Form 10-K Financial Statement

#000121390024023093 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SRTS
Sensus Healthcare, Inc. Stock $srts